Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861140 | 0.91 | TSHR (0.60) | TSHRHTTMAOBNQO2HPGD | |
| SCHEMBL9887618 | 0.84 | ALDH1A1 (0.56) | TSHRHTTHDAC3HDAC1HPGD | |
| SCHEMBL11230535 | 0.84 | HPGD (0.64) | TSHRHTTHDAC3HPGDSMN1; SMN2 | |
| SCHEMBL8652703 | 0.84 | TSHR (0.53) | TSHRHTTMAOBNQO2HPGD | |
| SCHEMBL23661975 | 0.82 | TSHR (0.56) | TSHRHTTHDAC3HDAC1HPGD | |
| SCHEMBL24333936 | 0.81 | TSHR (0.51) | TSHRHTTMAOBNQO2HPGD | |
| SCHEMBL11418358 | 0.80 | HTT (0.58) | TSHRHTTMAOBHPGDHCRTR1 | |
| SCHEMBL890994 | 0.80 | ALDH1A1 (0.62) | TSHRHTTHDAC3HDAC1MAOB | |
| SCHEMBL1659899 | 0.80 | HTT (0.61) | TSHRHTTMAOBHPGDSMN1; SMN2 | |
| SCHEMBL12462425 | 0.80 | NPC1 (0.68) | HDAC3HDAC1HPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | FISH & RICHARDSON PC | 2022-04-21 | — | — | US | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020053815-A1 | RELEASABLE GLP-1 CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | GLP1R, GIPR, IAPP | TSHR 181/4885HTT 692/4885HDAC3 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.